Geriatric population increasingly require therapies that offer glycemic control, weight reduction benefits, and broader cardiometabolic support
The calculation depends on your final concentration
Phase 2 trials used a structured titration protocol, typically starting at 0.5 mg once weekly and escalating to maintenance doses of up to 12 mg once weekly
You should not take retatrutide if you have: A personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 A history of pancreatitis Severe gastrointestinal disease, including gastroparesis Known hypersensitivity to any component of the drug You should use extreme caution and only proceed under close medical supervision if you have: Gallbladder disease or a history of gallstones Kidney disease, since dehydration from GI side effects can accelerate kidney damage Diabetic retinopathy, as rapid glucose changes can worsen it A history of eating disorders, since appetite suppression this powerful can interact badly with disordered eating patterns Retatrutide is also not approved for use in pregnancy
Commenting on future research, Gasoyan told MNT that future studies should examine the comparative effectiveness of treatments for obesity in patients who discontinue their novel GLP-1 RA or dual receptor agonist medication. We are already working on the next study, where we examine the comparative effectiveness of alternative treatment options for obesity in patients who discontinue semaglutide or tirzepatide, to help patients and their clinicians make informed decisions
The problem is that this would be significantly expensive for the states
